HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.

ABSTRACT:

Background

HSD3B1 (1245A>C) has been mechanistically linked to castration-resistant prostate cancer because it encodes an altered enzyme that augments dihydrotestosterone synthesis from non-gonadal precursors. We postulated that men inheriting the HSD3B1 (1245C) allele would exhibit resistance to androgen-deprivation therapy (ADT).

Methods

In this multicohort study, we determined HSD3B1 genotype retrospectively in men treated with ADT for post-prostatectomy biochemical failure and correlated genotype with long-term clinical outcomes. We used data and samples from prospectively maintained prostate cancer registries at the Cleveland Clinic (Cleveland, OH, USA; primary study cohort) and the Mayo Clinic (Rochester, MN, USA; post-prostatectomy and metastatic validation cohorts).

SUBMITTER: Hearn JWD 

PROVIDER: S-EPMC5135009 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature